Search
Displaying 261–270 of 737 for “retinitis clinical trial”
-
The RD Fund Announces Ocuphire Pharma’s Acquisition of Opus Genetics
In the PressThe resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD).
-
Dan Day - Making a Difference Now and for Future Generations
Beacon Stories“Because I have seen such tremendous progress over the years, and I want that progress to continue until the day when we have cures for all retinal diseases, it is important to me that the Foundation be part of my lasting legacy.”
-
ARVO 2021 Highlight: CRISPR/Cas9 Therapy Emerging for Dominant RP Caused by RP1 Mutations
Research NewsGene-editing approaches are often better suited for autosomal dominant retinal diseases than gene replacement therapies
-
AGTC Announces Development of Stargardt Disease Gene Therapy
Research NewsDual-vector delivery system designed to deliver the large ABCA4 gene
-
A Change in Identity Might Someday Save Vision
Research NewsBy changing the identity of cells in the retina–namely rods–researchers may someday be able to slow or halt vision loss for those with retinitis pigmentosa (RP) and other related conditions.
-
Despite Blindness, the Peaches are Sweet in Paran
Research NewsThe story of vision loss in a Peruvian village
-
Research News
More good news about treatments and technological advances for restoring vision for people with retinal diseases.
-
Second Sight Agrees to Merger to Maintain Retinal and Cortical Prostheses Programs
Research NewsCompany has been unable to meet revenue goals for the Argus II®
-
Stargardt Disease Research Advances
Research NewsRecent developments in research on Stargardt disease.
